that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer . Nat Med 2004 ; 10 : 145 – 147 . 11. Hurwitz H Fehrenbacher L Novotny W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
Search Results
Novel Approaches to Advanced Breast Cancer: Bevacizumab and Lapatinib
Erica L. Mayer, Nancy U. Lin, and Harold J. Burstein
Bevacizumab for Recurrent Glioblastoma Multiforme: A Meta-Analysis
Eric T. Wong, Shiva Gautam, Christopher Malchow, Melody Lun, Edward Pan, and Steven Brem
vasculature improves glioblastoma response to radiation therapy, 2 probably through increasing oxygen delivery and allowing radiation to work better in a normoxic rather than a hypoxic tumor microenvironment. 2 , 3 Bevacizumab, a monoclonal antibody against
Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non–Small Cell Lung Cancer
Stephen J. Bagley, Suzanna Talento, Nandita Mitra, Neal J. Meropol, Roger B. Cohen, Corey J. Langer, and Anil Vachani
patients lack a targetable mutation, carboplatin/pemetrexed alone or with the antiangiogenic monoclonal antibody bevacizumab remains a relevant systemic regimen. Bevacizumab was initially approved for nonsquamous NSCLC in 2006 based on results of the
Stereotactic Radiosurgery and Bevacizumab for Recurrent Glioblastoma Multiforme
Alvin R. Cabrera, Kyle C. Cuneo, James J. Vredenburgh, John H. Sampson, and John P. Kirkpatrick
bevacizumab, followed by temozolomide, bevacizumab, and irinotecan (CPT-11). Four weeks after surgery, he began radiotherapy (volumetric modulated arc therapy), receiving 50.4 Gy to the left frontoparietal region with a 9-Gy boost to the tumor bed over 6
Phase I Clinical Trial of Bendamustine and Bevacizumab for Patients With Advanced Cancer
Apostolia M. Tsimberidou, Alexandra M. Adamopoulos, Yang Ye, Sarina Piha-Paul, Filip Janku, Siqing Fu, David Hong, Gerald S. Falchook, Aung Naing, Jennifer Wheler, Adoneca Fortier, Razelle Kurzrock, and Kenneth R. Hess
patients with small cell lung cancer treated with single-agent bendamustine 5 or bendamustine combined with carboplatin, 4 the overall response rates were 29% and 73%, respectively. Bevacizumab is a recombinant humanized antibody directed against
Is the Battle Over Bevacizumab Coverage Looming?
Catherine Larkin
The FDA's approval of the cancer drug bevacizumab (Avastin; Roche/Genentech) in February 2004 validated a 30-year-old theory, championed by Judah Folkman, MD, of Harvard, that tumors can be stopped by choking off their blood supply. Enthusiasm for
Biologics in Cervical Cancer Therapy
Lyndsay J. Willmott, Daniele A. Sumner, and Bradley J. Monk
histologic microvessel density counts. Hawighorst et al. 18 evaluated primary tumors treated with radical hysterectomy, and found that the exchange rate constant was a significant predictor of poor patient survival. VEGF Targeted Therapy Bevacizumab
Chemotherapy for Metastatic Colorectal Cancer
Joseph Rosales and Lucille A. Leong
): 3525 . 15 Hurwitz H Fehrenbacher L Novotny W . Bevacizumab plus irinotecan, Fluorouracil, and leucovorin for metastatic colorectal cancer . N Engl J Med 2004 ; 350 : 2335 – 2342 . 16 Giantonio BJ Catalano PJ Meropol NJ . High
A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma
David A. Reardon, Scott Turner, Katherine B. Peters, Annick Desjardins, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon II, Lee W. Jones, John P. Kirkpatrick, Allan H. Friedman, James J. Vredenburgh, Darell D. Bigner, and Henry S. Friedman
radiographic responses and improved progression-free survival with bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), 7 among patients with recurrent malignant glioma. 8 – 11 However, initial enthusiasm has been
The Role of Bevacizumab in Glioblastoma
L. Burt Nabors
sequelae result in a marked deterioration in neurologic function which, in turn, results in a diminished quality of life in an already vulnerable patient population. The initial FDA approval for the use of bevacizumab in GBM, and its resulting inclusion
